Alligator Bioscience ABFRA:7AL0 39 Market Cap is €10.02 Mil as of Jun. 30, 2026. GuruFocus rates FRA:7AL0 with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 1,428 Biotechnology companies, Alligator Bioscience AB ranks worse than 83.26% on this metric.
Alligator Bioscience AB's quarterly market cap
declined
from Sep. 2025 (€20.11 Mil) to Dec. 2025 (€10.94 Mil) and
declined
from Dec. 2025 (€10.94 Mil) to Mar. 2026 (€0.06 Mil).
Alligator Bioscience AB's annual market cap
declined
from Dec. 2023 (€46.96 Mil) to Dec. 2024 (€15.52 Mil) and
declined
from Dec. 2024 (€15.52 Mil) to Dec. 2025 (€10.94 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alligator Bioscience AB's Enterprise Value for Today is €9.96 Mil.
Alligator Bioscience AB (FRA:7AL0) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Alligator Bioscience AB Market Cap Related Terms
Alligator Bioscience AB Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7AL0 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Alligator Bioscience AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alligator Bioscience AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Alligator Bioscience AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Alligator Bioscience AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alligator Bioscience AB (FRA:7AL0) has a Market Cap of €10.02 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alligator Bioscience AB and its competitors. According to the industry distribution chart, Alligator Bioscience AB ranks #1189 out of 1428 companies in the Biotechnology industry, placing it in the top 83.3%.
Is Alligator Bioscience AB's Market Cap too high?
Alligator Bioscience AB's current Market Cap is €10.02 Mil. Based on the distribution chart, Alligator Bioscience AB ranks #1189 out of 1428 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alligator Bioscience AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Alligator Bioscience AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #1189 out of 1428 companies for Market Cap. This places Alligator Bioscience AB in the lower half of its industry. The industry median Market Cap is 119.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alligator Bioscience AB and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alligator Bioscience AB's current Market Cap is €10.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Alligator Bioscience AB (FRA:7AL0) has a current Market Cap of €10.02 Mil. The current Market Cap is €10.02 Mil. Alligator Bioscience AB's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Alligator Bioscience AB (FRA:7AL0), the current Market Cap is €10.02 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
39GF Score
Get the complete analysis for FRA:7AL0
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7AL0 has been successfully added to your 
